PapersFlow Research Brief
Prostate Cancer Diagnosis and Treatment
Research Guide
What is Prostate Cancer Diagnosis and Treatment?
Prostate cancer diagnosis and treatment encompasses screening methods like PSA testing, diagnostic procedures including biopsy and imaging, local therapies such as radical prostatectomy and radiation, and systemic treatments including androgen deprivation therapy, chemotherapy with docetaxel, and novel hormonal agents like enzalutamide for advanced disease.
The field includes 110,430 published works on prostate cancer diagnosis and treatment. PSA-based screening reduces prostate cancer mortality by 20% but carries a high risk of overdiagnosis, as shown in a randomized European study (Schröder et al., 2009). Docetaxel combined with prednisone improves survival and quality of life compared to mitoxantrone plus prednisone in advanced prostate cancer (Tannock et al., 2004).
Research Sub-Topics
Prostate-Specific Antigen Dynamics
This sub-topic studies PSA kinetics, including velocity, density, and doubling time for early detection and monitoring of prostate cancer progression. Researchers evaluate thresholds, confounders, and predictive models in screening cohorts.
Multiparametric MRI for Prostate Cancer
Researchers investigate mpMRI protocols combining T2-weighted, diffusion, and dynamic contrast imaging for lesion detection and PI-RADS scoring. Studies assess diagnostic accuracy, biopsy targeting, and active surveillance applications.
Androgen Deprivation Therapy Resistance
This area examines molecular mechanisms of castration-resistant prostate cancer, including AR variants, neuroendocrine transdifferentiation, and lineage plasticity. Clinical trials test combination therapies to overcome resistance.
Prostate Cancer Genomic Subtypes
Researchers classify tumors using somatic mutations, copy number alterations, and gene fusions like TMPRSS2-ERG for prognostic and therapeutic stratification. Integration with transcriptomics reveals heterogeneity and evolutionary dynamics.
Prostate Cancer Active Surveillance
This sub-topic evaluates protocols for low-risk disease monitoring using serial PSA, MRI, and biopsies to defer treatment. Studies compare outcomes, reclassification rates, and patient-reported quality of life.
Why It Matters
Prostate cancer diagnosis and treatment directly impacts patient survival and healthcare systems, with PSA screening reducing death rates by 20% despite overdiagnosis risks (Schröder et al., 2009). Chemotherapy regimens like docetaxel plus prednisone extend survival in advanced cases, outperforming mitoxantrone plus prednisone (Tannock et al., 2004), while enzalutamide prolongs survival post-chemotherapy in metastatic castration-resistant disease (Scher et al., 2012). Recent FDA breakthrough designations for AI tools, such as ArteraAI Prostate for treatment decisions in localized cancer and biopsy assays, support precise interventions; for instance, the £1.9m Vanguard Path study tests ArteraAI in NHS hospitals to enhance diagnosis and treatment. Automated MRI systems and deep learning biomarkers from MRI improve detection of clinically significant prostate cancer and risk stratification.
Reading Guide
Where to Start
"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" by Tannock et al. (2004) first, as it establishes the survival benefit of docetaxel as a foundational chemotherapy regimen with 5666 citations.
Key Papers Explained
Tannock et al. (2004) "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" set the standard for chemotherapy, showing superior survival versus mitoxantrone; Petrylak et al. (2004) "Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer" built on this by comparing docetaxel-estramustine, extending median survival by nearly two months. Scher et al. (2012) "Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy" advanced post-chemotherapy options with enzalutamide prolonging survival in castration-resistant disease. Schröder et al. (2009) "Screening and Prostate-Cancer Mortality in a Randomized European Study" provides diagnostic context with 20% mortality reduction from PSA screening. D’Amico (1998) "Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer" compares local therapies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints highlight PSMA-based therapy sequencing, personalized intensification for hormone-sensitive prostate cancer, and rising metastatic incidence with 20% five-year survival. FDA breakthrough designations for ArteraAI Prostate tools aid treatment decisions and biopsies; automated MRI systems and foundation models enable noninvasive grading. GitHub tools like Aneja-Lab-Yale deep learning for MRI biomarkers and prostate cancer grade assessment from histopathology represent active implementation.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for ... | 2004 | New England Journal of... | 5.7K | ✕ |
| 2 | Decision Curve Analysis: A Novel Method for Evaluating Predict... | 2006 | Medical Decision Making | 4.9K | ✓ |
| 3 | Increased Survival with Enzalutamide in Prostate Cancer after ... | 2012 | New England Journal of... | 4.5K | ✓ |
| 4 | Biochemical Outcome After Radical Prostatectomy, External Beam... | 1998 | JAMA | 4.5K | ✕ |
| 5 | Screening and Prostate-Cancer Mortality in a Randomized Europe... | 2009 | New England Journal of... | 4.0K | ✓ |
| 6 | Docetaxel and Estramustine Compared with Mitoxantrone and Pred... | 2004 | New England Journal of... | 3.7K | ✓ |
| 7 | The American Urological Association Symptom Index for Benign P... | 1992 | The Journal of Urology | 3.4K | ✕ |
| 8 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screenin... | 2016 | European Urology | 3.2K | ✓ |
| 9 | EAU Guidelines on Prostate Cancer | 2007 | European Urology | 3.1K | ✓ |
| 10 | The Molecular Taxonomy of Primary Prostate Cancer | 2015 | Cell | 3.1K | ✓ |
In the News
FDA grants breakthrough device designation for ArteraAI Prostate tool
ArteraAI Prostate was recently granted breakthrough device designation by the FDA, Artera announced in a news release.1
FDA grants Breakthrough Device Designation to ArteraAI Prostate Tool
* ArteraAI Prostate, an AI-based tool, received FDA Breakthrough Device Designation for localized prostate cancer treatment decisions.
An MRI–pathology foundation model for noninvasive diagnosis and grading of prostate cancer
scalable, noninvasive approach to prostate cancer diagnosis and grading, offering a robust tool to support clinical decision-making while reducing reliance on biopsies.
Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation
Prostate MRI enables detection of clinically significant prostate cancer (csPCa), yet variability in PI-RADS scoring limits reproducibility and throughput. Here, we report the development and valid...
NHS hospitals to test AI tool that helps diagnose and treat prostate cancer
The £1.9m Vanguard Path study, funded by Prostate Cancer UK and led by researchers at the University of Oxford, is expected to last three years and will test an AI tool called the ArteraAI Prostate...
Code & Tools
Deep learning algorithms that generate prognostic biomarkers from MRI images to improve risk stratification of prostate cancer patients ### Licens...
healthcare cancer-research cancer-detection prostate-cancer machinelearning-python prostate-cancer-detection prostate-cancer-biopsies Update...
Prostate cancer is one of the most commonly diagnosed non-cutaneous malignant tumors and the sixth major cause of cancer-related death generally fo...
This repository contains the implementation of a Prostate Cancer Grade Assessment system, aimed at aiding in the accurate grading of prostate cance...
## Repository files navigation # Prostate Cancer Phenotyping NLP This is the code for the metastatic prostate cancer NLP system described in JCO ...
Recent Preprints
Recent Advances in Diagnosis and Treatment of Prostate Cancer - PubMed
The incidence of metastatic prostate cancer (mPC) in the U.S. has increased in the past 20 years, five-year survival after diagnosis is only about 20 % and treatment represents a major health care ...
Personalized intensification of treatment for hormone-sensitive prostate cancer
Historically, systemic therapy for hormone-sensitive prostate cancer (HSPC) was predicated on androgen-deprivation therapy (ADT) alone. However, in the past decade, substantial improvements have be...
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
Prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer cells relative to other cells. The increased expression and enzymatic activity of PSMA in high-stage disease confers a se...
Understanding prostate cancer care: recent progress and ...
We are pleased to share this topic collection focusing on the recent progress we have seen in prostate cancer. The landscape for prostate cancer research and policy is exciting: improved biological...
Latest Developments
Recent developments in prostate cancer diagnosis and treatment research include the promising results of the phase 3 trial comparing ^177Lu-PSMA-617 to androgen receptor pathway inhibitor therapy in taxane-naive metastatic castration-resistant prostate cancer patients, showing potential benefits in progression-free survival as of September 2024 (The Lancet01653-2/abstract), PubMed). Additionally, advancements include the development of automated MRI systems for detecting clinically significant prostate cancer, with validation published in November 2025 (Nature Communications).
Sources
Frequently Asked Questions
What survival benefit does docetaxel provide in advanced prostate cancer?
Docetaxel every three weeks with prednisone led to superior survival, pain response, PSA level reduction, and quality of life compared to mitoxantrone plus prednisone (Tannock et al., 2004). This regimen is standard for metastatic castration-resistant prostate cancer. The study involved patients with advanced disease and demonstrated clear clinical advantages.
How does PSA screening affect prostate cancer mortality?
PSA-based screening reduced the rate of death from prostate cancer by 20% in a randomized European study (Schröder et al., 2009). It was associated with a high risk of overdiagnosis. The trial was registered as ISRCTN49127736.
What is the role of enzalutamide after chemotherapy?
Enzalutamide significantly prolonged survival in men with metastatic castration-resistant prostate cancer after chemotherapy (Scher et al., 2012). The AFFIRM trial (NCT00974311) confirmed this benefit. It is funded by Medivation and Astellas Pharma.
How do outcomes compare for radical prostatectomy, radiation, and brachytherapy?
Low-risk patients had similar 5-year PSA outcomes across radical prostatectomy, external beam radiation, or interstitial radiation with or without neoadjuvant androgen deprivation (D’Amico, 1998). Intermediate- and high-risk patients fared better with surgery or external beam radiation than brachytherapy. Prospective validation confirmed these findings.
What do EAU guidelines recommend for screening and diagnosis?
EAU-ESTRO-SIOG Guidelines cover screening, diagnosis, and local curative treatments (Mottet et al., 2016). EAU Guidelines on Prostate Cancer provide comprehensive recommendations (Heidenreich et al., 2007). These serve as key references for clinical practice.
Open Research Questions
- ? How can overdiagnosis from PSA screening be minimized while preserving mortality benefits?
- ? What sequencing optimizes PSMA-based therapies with hormonal and chemotherapeutic agents in metastatic disease?
- ? Which molecular subtypes of primary prostate cancer predict response to intensified hormone-sensitive treatments?
- ? How do AI-driven MRI biomarkers improve risk stratification beyond PI-RADS scoring?
- ? What combinations of androgen receptor pathway inhibitors with ADT yield the best survival in high-risk hormone-sensitive prostate cancer?
Recent Trends
FDA granted breakthrough device designation to ArteraAI Prostate for localized cancer treatment decisions and biopsy assays tested in NHS £1.9m Vanguard Path study.
2025Preprints emphasize PSMA therapy combinations, ADT intensification for hormone-sensitive disease, and rising U.S. metastatic incidence with 20% five-year survival.
Automated MRI for csPCa detection and MRI-pathology foundation models reduce biopsy reliance; GitHub repositories advance MRI biomarkers and NLP phenotyping.
Research Prostate Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Prostate Cancer Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.